At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 87 enrolled
Drug / intervention
ZW25 (Zanidatamab)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
In Brief
A Phase 2 clinical trial evaluating ZW25 (Zanidatamab) for HER2-amplified Biliary Tract Cancers. Completed, enrolled 87 participants across 67 sites in 9 countries.
Detailed Summary
This multicenter, open-label, single-arm trial will evaluate the anti-tumor activity of ZW25 (zanidatamab) monotherapy in subjects with human epidermal growth factor receptor 2 (HER2)-amplified, inoperable and advanced or metastatic biliary tract cancer (BTC), including intra-hepatic cholangiocarcinoma (ICC), extra-hepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHER2-amplified Biliary Tract Cancers
CountriesCanada, Chile, China, France, Italy, South Korea, Spain, United Kingdom, United States
CollaboratorsBeiGene, Jazz Pharmaceuticals Ireland Limited, BeOne Medicines LTD
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartOct 2020
Primary CompletionJul 2023
Study CompletionJul 2024
TodayJul 2026
First PostedJul 10, 2020
Enrollment StartOct 1, 2020
Primary CompletionJul 28, 2023
Study CompletionJul 11, 2024
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 6.0 years ago
Interventions
ZW25 (Zanidatamab)drug
Administered intravenously